Quantcast

East and Central Asia

Hutschison China MediTech get’s priority review status for its anti-cancer drug surufatinib

Hutchison China MediTech Limited said on Friday that it got approval from the China’s authority, the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), a Priority Review status to the New Drug Application (NDA) for surufatinib, for the treatment of patients with advanced non-pancreatic neuroendocrine tumors (NET).

Posted in Asia, news | Tagged , | Leave a comment

ViGeneron closes Series A round which attracts WuXi AppTec and Sequoia Capital China

ViGeneron GmbH, a gene therapy company, announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China, which will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs.

Posted in Asia, news | Tagged , | Leave a comment

Chugai’s Hemlibra Approved for Hemophilia A Without Inhibitors in Taiwan

Hemlibra was approved for hemophilia A without inhibitors in Taiwan on 22 October 2019. Read the full article

Posted in Asia, news | Tagged , | Leave a comment

EMA and FDA Accept Marketing Applications for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)

NMOSD is a rare disease where repeated relapses may result in visual impairment and motor disability in the course of

Posted in Asia, news | Tagged | Leave a comment

Vaxess and GC Pharma to Collaborate on Development of Highly Effective Influenza Vaccine Smart Release Patch

Vaxess and GC Pharma will collaborate on Influenza vaccine smart release patch, in a deal which will give Vaxess exclusive

Posted in Asia, news | Tagged , , | Leave a comment

Kangpu Biopharmaceuticals doses first humans with KPG-818 for treating SLE and hematological malignancies

Kangpu Biopharmaceuticals has completed a first-in-human phase I single ascending dose (SAD) clinical study in the United States, testing KPG-818 for the treatment of SLE and hematological malignancies.

Posted in Asia, news, North America | Tagged , | Leave a comment

Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in China for Malignant Ascites

CHENGDU, China–(BUSINESS WIRE)–Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first

Posted in Asia, news | Tagged , | Leave a comment

Shionogi to Present New Data at IDWeek 2019

– Including Cefiderocol Phase III APEKS-NP Trial as Late-breaker Oral Presentation – OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE)–Shionogi &

Posted in Asia, news | Tagged | Leave a comment

Takeda presents efficacy for nacrolepsy type 1 Orexin receptor agonist TAK-925

Takeda’s presentation has shown TAK-925 was well tolerated in patients with narcolepsy type 1 and increased wakefulness compared to placebo.

Posted in Asia, news, North America | Tagged , , | Leave a comment

Entyvio shows superiority over Humira in first head-to-head biologic study in ulcerative colitis

Takeda announced further results from the Varsity study, which demonstrated the superiority of the gut-selective biologic vedolizumab (Entyvio) to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira) in achieving the primary endpoint of clinical remission at week 52 in patients with moderately to severely active ulcerative colitis

Posted in Asia, Europe, news | Tagged , , , | Leave a comment